Related Experiment Video
Updated: Jun 4, 2025
06:27
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
Published on: January 10, 2025
667
GLP-1RA based therapies in the young and old
Georgia Rigas1,2, Shirley Alexander3,4, Cilla J Haywood5,6,7
1St George & Sutherland Clinical School, University of New South Wales - Medicine.
Current Opinion in Endocrinology, Diabetes, and Obesity
|December 18, 2024
Summary
Glucagon-like peptide-1 receptor agonist-based therapies (GLP1BTs) show promise for managing obesity in younger individuals and older adults. Recent findings support their use, with no new safety concerns identified in older populations.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Obesity is a chronic, progressive disease driven by dysfunctional adipocytes.
- Glucagon-like peptide-1 receptor agonist-based therapies (GLP1BTs) offer significant weight loss and health benefits in adults.
- Growing interest exists in applying GLP1BTs to pediatric and geriatric populations.
Purpose of the Study:
- To review current data on GLP1BTs for managing obesity in younger individuals.
- To evaluate the efficacy and safety of GLP1BTs in older adults (over 65).
- To assess the role of GLP1BTs in youth-onset Type 2 diabetes (YOT2D).
Main Methods:
- Systematic review of recently published clinical trial data.
- Analysis of American Pediatric Guidelines regarding obesity management medication (OMM).
- Translation of adult GLP1BT trial data for applicability to individuals over 65.
Main Results:
- GLP1BTs are increasingly recommended for early obesity management in youth.
- Published data support GLP1BT use in older adults with obesity and/or Type 2 diabetes (T2D).
- No novel safety signals were identified in the geriatric population studied.
Conclusions:
- Newer GLP1BTs represent a significant advancement in managing younger individuals with metabolic dysfunction.
- Cardiovascular outcome trial (CVOT) data confirm the utility and safety of GLP1BTs in older adults.
- Further long-term data and studies in diverse health complexities will enhance understanding of GLP1BTs in older populations.
More Related Videos
06:34Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
187
09:31Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
7.2K
Related Concept Videos
01:24Glucagon-like Receptor Agonists
297
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
297
01:16Insulin: Dosing Regimen and Adverse Effects
142
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
142
01:06Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136
01:23Dipeptidyl Peptidase 4 Inhibitors
167
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
167
01:15Hypoglycemia and Glucagon
150
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
150
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
168
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
168